Last reviewed · How we verify

Darunavir, Ritonavir and Etravirine

Imperial College London · FDA-approved active Small molecule

Darunavir, Ritonavir and Etravirine is a Antiretroviral combination (protease inhibitor + NNRTI) Small molecule drug developed by Imperial College London. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients with resistance to other antiretrovirals. Also known as: Prezista, Norvir, Intelence.

This combination inhibits HIV protease and reverse transcriptase to block viral replication in HIV-infected patients.

This combination inhibits HIV protease and reverse transcriptase to block viral replication in HIV-infected patients. Used for HIV-1 infection in treatment-experienced patients with resistance to other antiretrovirals.

At a glance

Generic nameDarunavir, Ritonavir and Etravirine
Also known asPrezista, Norvir, Intelence
SponsorImperial College London
Drug classAntiretroviral combination (protease inhibitor + NNRTI)
TargetHIV protease, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Darunavir and ritonavir are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, while etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks reverse transcriptase activity. Together, they target multiple steps of the HIV replication cycle to suppress viral load.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Darunavir, Ritonavir and Etravirine

What is Darunavir, Ritonavir and Etravirine?

Darunavir, Ritonavir and Etravirine is a Antiretroviral combination (protease inhibitor + NNRTI) drug developed by Imperial College London, indicated for HIV-1 infection in treatment-experienced patients with resistance to other antiretrovirals.

How does Darunavir, Ritonavir and Etravirine work?

This combination inhibits HIV protease and reverse transcriptase to block viral replication in HIV-infected patients.

What is Darunavir, Ritonavir and Etravirine used for?

Darunavir, Ritonavir and Etravirine is indicated for HIV-1 infection in treatment-experienced patients with resistance to other antiretrovirals.

Who makes Darunavir, Ritonavir and Etravirine?

Darunavir, Ritonavir and Etravirine is developed and marketed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

Is Darunavir, Ritonavir and Etravirine also known as anything else?

Darunavir, Ritonavir and Etravirine is also known as Prezista, Norvir, Intelence.

What drug class is Darunavir, Ritonavir and Etravirine in?

Darunavir, Ritonavir and Etravirine belongs to the Antiretroviral combination (protease inhibitor + NNRTI) class. See all Antiretroviral combination (protease inhibitor + NNRTI) drugs at /class/antiretroviral-combination-protease-inhibitor-nnrti.

What development phase is Darunavir, Ritonavir and Etravirine in?

Darunavir, Ritonavir and Etravirine is FDA-approved (marketed).

What are the side effects of Darunavir, Ritonavir and Etravirine?

Common side effects of Darunavir, Ritonavir and Etravirine include Diarrhea, Nausea, Headache, Rash, Elevated liver enzymes.

What does Darunavir, Ritonavir and Etravirine target?

Darunavir, Ritonavir and Etravirine targets HIV protease, HIV reverse transcriptase and is a Antiretroviral combination (protease inhibitor + NNRTI).

Related